Nasal dosage forms of propranol
AssigneeUniversity of Kentucky Research Foundation
InventorsAnwar A. Hussain, Shinichiro Hirai, Rima Bawarshi
Life of this patent
Estimating the term…
Abstract
The invention relates to a novel method of administering propranolol, a known .beta.-adrenergic blocking agent widely used in the treatment of angina pectoris, arrhythmias, hypertension and other cardiac conditions, and migraine. The invention further relates to novel dosage forms of propranolol which are adapted for nasal administration and which include solutions, suspensions, gels and ointments.
Claims11
A pharmaceutically acceptable nasal composition, in dosage unit form, for nasal administration to obtain a systemic therapeutic .beta.-adrenergic blocking response in a warm-blooded animal, consisting essentially of, per nasal dosage unit, (i) a systemically therapeutically effective unit .beta.-adrenergic blocking amount of a compound having the formula ##STR2## or a nontoxic pharmaceutically acceptable ester of salt thereof, and (ii) a nontoxic pharmaceutically acceptable nasal carrier therefor, said composition being formulated as a nasal ointment or a nasal gel adapted for sustained release to the nasal mucosa.
A pharmaceutically acceptable nasal composition, in dosage unit form, for nasal administration to obtain a systemic therapeutic .beta.-adrenergic blocking response in a warm-blooded animal, consisting essentially of, per nasal dosage unit, (i) a systemically therapeutically effective unit .beta.-adrenergic blocking amount of propranolol stearate, and (ii) a nontoxic pharmaceutically acceptable nasal carrier therefor.
Propranolol stearate.
Dependencies are inferred from the claim text.